Al-Ani A, Prentice RE, Rentsch CA, et al. Review article: prevention, diagnosis, and management of COVID-19 in the inflammatory bowel disease patient. Aliment Pharmacol Therapeut. 2020;52:54-72.
Allocca M, Fiorino G, Zallot C, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol. 2020. doi: 10.1016/j.cgh.2020.04.071. [Epub ahead of print]
Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:522‐529.
Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69:1213‐1217.
Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32:425‐440.
Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. SECURE-IBD Database Public Data Update. covidibd.org. Accessed June 2, 2020.
Cutolo M, Smith V, Paolino S. Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination. Clin Exp Rheumatol. 2020;38:383‐386.
Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017;76:364‐370.
EULAR.org. EULAR COVID-19 database. Accessed June 25, 2020.https://www.eular.org/myUploadData/files/eular_covid19_database_infographic_as_of_1_june.pdf
EULAR, Study on COVID-19 in the context of rheumatic and musculoskeletal diseases provides reassurance to patients on immunosuppressive medications. News release. June 6, 2020. Accessed June 25, 2020. https://www.eular.org/sysModules/obxContent/files/www.eular.2015/1_42291DEB-50E5-49AE-5726D0FAAA83A7D4/eular_press_release_covid_registry_final.pdf
Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020;2:e250‐e253.
Global Health 50/50. COVID-19: Data disaggregated by age and sex. Accessed June 25, 2020. https://globalhealth5050.org/covid19/age-and-sex-data/#1589893973981-6ca5e520-eb20
Haberman R, Axelrad J, Chen A, et al. COVID-19 in immune-mediated inflammatory diseases -- case series from New York. N Engl J Med. 2020. doi: 10.1056/NEJMc2009567. [Epub ahead of print].
Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 [published online ahead of print, 2020 Jun 5]. Ann Rheum Dis. 2020;79:851-858.
Magro F, Rahier J-F, Abeu C. Inflammatory bowel disease management during the COVID-19 outbreak: the 10 do's and don'ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020. [In press].
Matucci A, Vultaggio A, Danesi R. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Respir Res. 2018;19:154.
Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohn's Colitis. doi:10.1093/ecco-jcc/jjaa061. [Epub ahead of print].
Rubin DT, Abreu MT, Rai V, et al. International Organization for the Study of Inflammatory Bowel Disease. Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology. 2020. doi:10.1053/j.gastro.2020.04.002. [Epub ahead of print].
Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258‐265.
SECURE-IBD Database. Coronavirus and IBD reporting database. Accessed June 25, 2020. covidibd.org

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Maurizio Cutolo, MD

Professor of Rheumatology
University of Genoa School of Medicine
IRCCS San Martino Polyclinic Hospital
Genova, Italy

Disclosures

Disclosure: Maurizio Cutolo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene
Served as a speaker or a member of a speakers bureau for: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene
Received grants for clinical research from: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene

Bernard Combe, MD, PhD

Head
Department of Rheumatology
Montpellier University Hospital
Montpellier, France

Disclosures

Disclosure: Bernard Combe, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Eli Lilly; Gilead Sciences, Inc.; Janssen; Novartis; Roche-Chugai
Served as a speaker or a member of a speakers bureau for: AbbVie; Bristol Myers Squibb; Eli Lilly; Gilead Sciences, Inc.; Merck Sharp & Dohme; Roche-Chugai
Received grants for clinical research from: Novartis; Pfizer

Silvio Danese, MD, PhD

Professor of Gastroenterology
Head of IBD Unit
Division of Gastroenterolog
Humanitas University
Milan, Italy

Disclosures

Disclosure: Silvio Danese, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Allergan; Amgen; AstraZeneca; Athos Therapeutics; Biogen; Boehringer Ingelheim; Celgene; Celltrion; Eli Lilly; Enthera; Ferring Pharmaceuticals Inc.; Gilead Sciences, Inc.; Hospira; Inotrem; Janssen; Johnson & Johnson; Merck Sharp & Dohme; Mundipharma; Myland; Pfizer; Roche; Sandoz; Sublimity Therapeutics; Takeda; TiGenix; UCB Inc.

Axel Dignass, MD, PhD

Professor of Medicine and Gastroenterology
Head
Department of Medicine I Agaplesion Markus Hospital
Frankfurt, Germany

Disclosures

Disclosure: Axel Dignass, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Celgene; Falk; Ferring; Fresnius Kabi; Genentech; Hexal Janssen; Med Update GmbH; Merck Sharp & Dohme; Pfizer; Roche; Sandoz; Takeda; Tillotts; Thieme; Vifor
Served as a speaker or a member of a speakers bureau for: AbbVie; Cilag; Falk; Ferring; Janssen; Med Update GmbH; Merck Sharp & Dohme; Pfizer; Tillotts; Vifor

Editor

Walid Amara, MD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Servier
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude, Servier, Novartis, Amgen

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

CPD

Managing Patients on TNF Inhibitors During the COVID-19 Pandemic

Authors: Maurizio Cutolo, MD; Bernard Combe, MD, PhD; Silvio Danese, MD, PhD; Axel Dignass, MD, PhD
CPD Released: 7/31/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 7/31/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US rheumatologists, gastroenterologists, and pharmacists and other healthcare professionals involved in the management of patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).

The goal of this activity is to increase knowledge on the effect of coronavirus disease 2019 (COVID-19) on patients with RA and IBD and the management of these patients on tumor necrosis factor (TNF) inhibitors biosimilars in the COVID-19 pandemic.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- COVID-19 and its impact on patients with RA and IBD
- Expert guidance on continuation of immunosuppressive therapies in infected patients
Demonstrate greater confidence in their ability to
- Management of RA and IBD patients on TNF inhibitor biosimilars during the COVID-19 pandemic

Disclosures

Faculty

Maurizio Cutolo, MD

Professor of Rheumatology
University of Genoa School of Medicine
IRCCS San Martino Polyclinic Hospital
Genova, Italy

Disclosures

Disclosure: Maurizio Cutolo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene
Served as a speaker or a member of a speakers bureau for: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene
Received grants for clinical research from: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene

Bernard Combe, MD, PhD

Head
Department of Rheumatology
Montpellier University Hospital
Montpellier, France

Disclosures

Disclosure: Bernard Combe, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Eli Lilly; Gilead Sciences, Inc.; Janssen; Novartis; Roche-Chugai
Served as a speaker or a member of a speakers bureau for: AbbVie; Bristol Myers Squibb; Eli Lilly; Gilead Sciences, Inc.; Merck Sharp & Dohme; Roche-Chugai
Received grants for clinical research from: Novartis; Pfizer

Silvio Danese, MD, PhD

Professor of Gastroenterology
Head of IBD Unit
Division of Gastroenterolog
Humanitas University
Milan, Italy

Disclosures

Disclosure: Silvio Danese, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Allergan; Amgen; AstraZeneca; Athos Therapeutics; Biogen; Boehringer Ingelheim; Celgene; Celltrion; Eli Lilly; Enthera; Ferring Pharmaceuticals Inc.; Gilead Sciences, Inc.; Hospira; Inotrem; Janssen; Johnson & Johnson; Merck Sharp & Dohme; Mundipharma; Myland; Pfizer; Roche; Sandoz; Sublimity Therapeutics; Takeda; TiGenix; UCB Inc.

Axel Dignass, MD, PhD

Professor of Medicine and Gastroenterology
Head
Department of Medicine I Agaplesion Markus Hospital
Frankfurt, Germany

Disclosures

Disclosure: Axel Dignass, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Celgene; Falk; Ferring; Fresnius Kabi; Genentech; Hexal Janssen; Med Update GmbH; Merck Sharp & Dohme; Pfizer; Roche; Sandoz; Takeda; Tillotts; Thieme; Vifor
Served as a speaker or a member of a speakers bureau for: AbbVie; Cilag; Falk; Ferring; Janssen; Med Update GmbH; Merck Sharp & Dohme; Pfizer; Tillotts; Vifor

Editor

Walid Amara, MD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Servier
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude, Servier, Novartis, Amgen

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Managing Patients on TNF Inhibitors During the COVID-19 Pandemic

Authors: Maurizio Cutolo, MD; Bernard Combe, MD, PhD; Silvio Danese, MD, PhD; Axel Dignass, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 7/31/2020

Valid for credit through: 7/31/2021, 11:59 PM EST

processing....

Video quality may be reduced from our standard offering due to efforts to honor COVID-19 hygienic practices.

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Maurizio Cutolo, MD

Bernard Combe, MD, PhD

Silvio Danese, MD, PhD

Axel Dignass, MD, PhD

Editor

Walid Amara, MD

Content Reviewer

Robert Morris, PharmD

CPD

Managing Patients on TNF Inhibitors During the COVID-19 Pandemic

Target Audience and Goal Statement

Disclosures

Faculty

Maurizio Cutolo, MD

Bernard Combe, MD, PhD

Silvio Danese, MD, PhD

Axel Dignass, MD, PhD

Editor

Walid Amara, MD

Content Reviewer

Robert Morris, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Managing Patients on TNF Inhibitors During the COVID-19 Pandemic